Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with , gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.

Purpose: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimens in double-hit lymphoma (DHL) and gene copy number gain (CNG) lymphoma and to contrast the prognosis of these two disease types.

Methods: We retrospectively examined 127 cases of newly diagnosed diffuse large B-cell lymphoma (DLBCL), and used fluorescence in situ hybridization (FISH) to detect genetic abnormalities in and .

Results: In the two schemes, the 2-year progression-free survival (PFS) was higher for R-DA-EPOCH group than for R-CHOP (79.8% vs 57.5%, =0.002), this advantage was also reflected in 2-year overall survival (OS) (81.6% vs 58.5%, =0.002). In double CNG patients, R-DA-EPOCH regimen was significantly better than R-CHOP (=0.007 for PFS, =0.010 for OS), and R-DA-EPOCH has the same advantage in DHL patients (=0.001 for PFS, =0.047 for OS). For the two disease types, the PFS for DHL was inferior to that for double CNG (52.9% vs 72.4%, =0.008), while the OS was not significantly different (=0.050). Subgroup analysis showed that the PFS for double CNG with and was superior to that for DHL with and (=0.043), this trend is also seen in double CNG and DHL with and (=0.036). However, the OS was not significantly different between the two subgroups. Multivariate analyses showed that in DLBCL patients with genetic abnormality detected by FISH, the treatment and disease types were independent prognostic factors. The adverse reaction rates were similar in R-DA-EPOCH and R-CHOP (>0.05).

Conclusion: Our retrospective study shows that DHL has a poorer prognosis than double CNG. Based on its improved lifetime and good tolerance, R-DA-EPOCH is a promising regimen for DHL or double CNG, which is expected to become the first-line treatment for high-risk DLBCL types based on more clinical research.